| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | zinc ion binding | TET2 UBR5 LNPEP POLA1 RBM4B IGHMBP2 OTUD7A WT1 GATA5 MDM4 NR1D1 CBLB USP16 MNAT1 PGR | 1.30e-05 | 891 | 92 | 15 | GO:0008270 |
| GeneOntologyMolecularFunction | transition metal ion binding | TET2 RPLP2 UBR5 LNPEP POLA1 RBM4B IGHMBP2 OTUD7A WT1 GATA5 MDM4 ADNP NR1D1 CBLB USP16 MNAT1 PGR | 2.67e-05 | 1189 | 92 | 17 | GO:0046914 |
| GeneOntologyMolecularFunction | transcription coregulator binding | 4.64e-05 | 140 | 92 | 6 | GO:0001221 | |
| GeneOntologyCellularComponent | chromatin | NCOR1 ATF6 ARNT SCML2 HOXD1 ZBED4 UBR5 POLA1 ARNT2 GATA5 SIM1 MED1 SIX1 ADNP NR1D1 TP73 PGR | 2.94e-04 | 1480 | 94 | 17 | GO:0000785 |
| GeneOntologyCellularComponent | neuronal cell body | CNTNAP3B MYO5B LNPEP IGHMBP2 NUMA1 CNTNAP3 IGSF9B BSN ADNP NR1D1 GABBR1 PGR | 3.60e-04 | 835 | 94 | 12 | GO:0043025 |
| GeneOntologyCellularComponent | aryl hydrocarbon receptor complex | 5.50e-04 | 8 | 94 | 2 | GO:0034751 | |
| GeneOntologyCellularComponent | axon | CNTNAP3B NF1 USP9X IGHMBP2 CNTN5 CNTNAP3 ADGRL1 BSN ADNP GABBR1 PGR JAM2 | 6.41e-04 | 891 | 94 | 12 | GO:0030424 |
| GeneOntologyCellularComponent | cell body | CNTNAP3B MYO5B LNPEP IGHMBP2 NUMA1 CNTNAP3 IGSF9B BSN ADNP NR1D1 GABBR1 PGR | 9.23e-04 | 929 | 94 | 12 | GO:0044297 |
| GeneOntologyCellularComponent | insulin-responsive compartment | 1.07e-03 | 11 | 94 | 2 | GO:0032593 | |
| GeneOntologyCellularComponent | cell cortex region | 1.09e-03 | 45 | 94 | 3 | GO:0099738 | |
| GeneOntologyCellularComponent | somatodendritic compartment | CNTNAP3B NF1 MYO5B LNPEP IGHMBP2 NUMA1 CNTNAP3 IGSF9B BSN ADNP NR1D1 GABBR1 PGR JAM2 | 1.15e-03 | 1228 | 94 | 14 | GO:0036477 |
| GeneOntologyCellularComponent | transcription regulator complex | 1.45e-03 | 596 | 94 | 9 | GO:0005667 | |
| Domain | KH_1 | 3.58e-05 | 38 | 92 | 4 | PF00013 | |
| Domain | KH | 4.40e-05 | 40 | 92 | 4 | SM00322 | |
| Domain | KH_dom | 4.40e-05 | 40 | 92 | 4 | IPR004087 | |
| Domain | KH_TYPE_1 | 5.35e-05 | 42 | 92 | 4 | PS50084 | |
| Domain | KH_dom_type_1 | 6.44e-05 | 44 | 92 | 4 | IPR004088 | |
| Domain | PAS_fold_3 | 1.91e-04 | 23 | 92 | 3 | IPR013655 | |
| Domain | PAS_3 | 1.91e-04 | 23 | 92 | 3 | PF08447 | |
| Domain | PAS-assoc_C | 2.17e-04 | 24 | 92 | 3 | IPR000700 | |
| Domain | PAS | 2.46e-04 | 25 | 92 | 3 | PF00989 | |
| Domain | PAS_fold | 2.46e-04 | 25 | 92 | 3 | IPR013767 | |
| Domain | PAC | 2.77e-04 | 26 | 92 | 3 | IPR001610 | |
| Domain | PAC | 2.77e-04 | 26 | 92 | 3 | SM00086 | |
| Domain | PAC | 2.77e-04 | 26 | 92 | 3 | PS50113 | |
| Domain | PAS | 5.17e-04 | 32 | 92 | 3 | SM00091 | |
| Domain | PAS | 6.20e-04 | 34 | 92 | 3 | IPR000014 | |
| Domain | PAS | 6.20e-04 | 34 | 92 | 3 | PS50112 | |
| Domain | Nuc_translocat | 6.59e-04 | 8 | 92 | 2 | IPR001067 | |
| Domain | LAM_G_DOMAIN | 8.61e-04 | 38 | 92 | 3 | PS50025 | |
| Domain | - | 9.30e-04 | 39 | 92 | 3 | 3.30.1370.10 | |
| Domain | Laminin_G_2 | 1.00e-03 | 40 | 92 | 3 | PF02210 | |
| Domain | LamG | 1.32e-03 | 44 | 92 | 3 | SM00282 | |
| Domain | - | 2.79e-03 | 57 | 92 | 3 | 3.30.50.10 | |
| Domain | Laminin_G | 2.93e-03 | 58 | 92 | 3 | IPR001791 | |
| Domain | Znf_NHR/GATA | 2.93e-03 | 58 | 92 | 3 | IPR013088 | |
| Domain | USP_CS | 4.23e-03 | 66 | 92 | 3 | IPR018200 | |
| Domain | FA58C | 4.74e-03 | 21 | 92 | 2 | SM00231 | |
| Domain | FA58C_3 | 4.74e-03 | 21 | 92 | 2 | PS50022 | |
| Domain | FA58C_1 | 4.74e-03 | 21 | 92 | 2 | PS01285 | |
| Domain | FA58C_2 | 4.74e-03 | 21 | 92 | 2 | PS01286 | |
| Domain | - | 4.83e-03 | 222 | 92 | 5 | 1.25.10.10 | |
| Domain | USP_1 | 4.99e-03 | 70 | 92 | 3 | PS00972 | |
| Domain | UCH | 5.19e-03 | 71 | 92 | 3 | PF00443 | |
| Domain | USP_2 | 5.19e-03 | 71 | 92 | 3 | PS00973 | |
| Domain | USP_3 | 5.40e-03 | 72 | 92 | 3 | PS50235 | |
| Domain | USP_dom | 5.40e-03 | 72 | 92 | 3 | IPR028889 | |
| Domain | Peptidase_C19_UCH | 5.40e-03 | 72 | 92 | 3 | IPR001394 | |
| Domain | F5_F8_type_C | 6.17e-03 | 24 | 92 | 2 | PF00754 | |
| Domain | FA58C | 6.17e-03 | 24 | 92 | 2 | IPR000421 | |
| Domain | ARM-type_fold | 6.60e-03 | 339 | 92 | 6 | IPR016024 | |
| Domain | - | 6.72e-03 | 449 | 92 | 7 | 3.30.40.10 | |
| Domain | Znf_RING/FYVE/PHD | 7.54e-03 | 459 | 92 | 7 | IPR013083 | |
| Domain | CRAL-TRIO_dom | 8.35e-03 | 28 | 92 | 2 | IPR001251 | |
| Pubmed | Pooled-matrix protein interaction screens using Barcode Fusion Genetics. | TSNAXIP1 NCOR1 ARNT HAUS1 NCAPD2 WT1 TNS2 HOOK2 ANKHD1 MDM4 CBLB MNAT1 SEMA4G | 1.17e-10 | 419 | 94 | 13 | 27107012 |
| Pubmed | Proteome-scale mapping of binding sites in the unstructured regions of the human proteome. | 2.50e-08 | 430 | 94 | 11 | 35044719 | |
| Pubmed | Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes. | NCOR1 ATF6 ARNT UBR5 PLEKHG4 HIPK1 NCAPD2 SIX1 ANKHD1 MDM4 ADNP NOVA1 LRRFIP2 NOVA2 | 7.70e-08 | 857 | 94 | 14 | 25609649 |
| Pubmed | 1.57e-07 | 147 | 94 | 7 | 29576527 | ||
| Pubmed | NF1 LMNA RPLP2 UBR5 POLA1 USP9X NUMA1 NCAPD2 FRYL ANKHD1 ADNP DDB1 | 2.04e-07 | 653 | 94 | 12 | 22586326 | |
| Pubmed | Separate necdin domains bind ARNT2 and HIF1alpha and repress transcription. | 3.80e-07 | 6 | 94 | 3 | 17826745 | |
| Pubmed | 3.80e-07 | 6 | 94 | 3 | 8927054 | ||
| Pubmed | A central chaperone-like role for 14-3-3 proteins in human cells. | TET2 ABLIM1 NF1 RPLP2 CCSER2 OTUD7A FRYL PEAK1 PPIP5K2 MDM4 MEX3B DENND4C DOP1B | 5.70e-07 | 861 | 94 | 13 | 36931259 |
| Pubmed | MAGED1 is a novel regulator of a select subset of bHLH PAS transcription factors. | 6.64e-07 | 7 | 94 | 3 | 27472814 | |
| Pubmed | 6.64e-07 | 7 | 94 | 3 | 27782878 | ||
| Pubmed | 1.06e-06 | 8 | 94 | 3 | 11782478 | ||
| Pubmed | NCOR1 LMNA RPLP2 USP9X NUMA1 NCAPD2 MED1 BRAT1 CTTNBP2NL DENND4C | 1.12e-06 | 503 | 94 | 10 | 16964243 | |
| Pubmed | NCOR1 ABLIM1 SCML2 USP9X NUMA1 NCAPD2 PEAK1 MED1 ANKHD1 ADNP | 2.44e-06 | 549 | 94 | 10 | 38280479 | |
| Pubmed | 3.11e-06 | 11 | 94 | 3 | 11381139 | ||
| Pubmed | Reciprocal interaction between SIRT6 and APC/C regulates genomic stability. | 3.15e-06 | 440 | 94 | 9 | 34244565 | |
| Pubmed | 4.68e-06 | 591 | 94 | 10 | 15231748 | ||
| Pubmed | A census of human transcription factors: function, expression and evolution. | ATF6 ARNT HOXD1 ZBED4 ARNT2 WT1 GATA5 SIX1 ADNP NR1D1 TP73 PGR | 6.26e-06 | 908 | 94 | 12 | 19274049 |
| Pubmed | Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation. | NF1 LMNA RPLP2 POLA1 USP9X PSMB2 NUMA1 NCAPD2 PEAK1 BSN ANKHD1 ADNP DDB1 LANCL2 LRRFIP2 | 6.35e-06 | 1425 | 94 | 15 | 30948266 |
| Pubmed | 7.23e-06 | 2 | 94 | 2 | 15466261 | ||
| Pubmed | 7.23e-06 | 2 | 94 | 2 | 9789075 | ||
| Pubmed | 7.23e-06 | 2 | 94 | 2 | 25482556 | ||
| Pubmed | Crystal structures of Nova-1 and Nova-2 K-homology RNA-binding domains. | 7.23e-06 | 2 | 94 | 2 | 10368286 | |
| Pubmed | WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. | 7.23e-06 | 2 | 94 | 2 | 25601757 | |
| Pubmed | 7.23e-06 | 2 | 94 | 2 | 21512513 | ||
| Pubmed | 7.23e-06 | 2 | 94 | 2 | 26807827 | ||
| Pubmed | 7.23e-06 | 2 | 94 | 2 | 31597742 | ||
| Pubmed | The tetranucleotide UCAY directs the specific recognition of RNA by the Nova K-homology 3 domain. | 7.23e-06 | 2 | 94 | 2 | 10811881 | |
| Pubmed | 7.23e-06 | 2 | 94 | 2 | 32932609 | ||
| Pubmed | UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability. | 7.23e-06 | 2 | 94 | 2 | 37478846 | |
| Pubmed | 7.23e-06 | 2 | 94 | 2 | 17023418 | ||
| Pubmed | 7.23e-06 | 2 | 94 | 2 | 31150793 | ||
| Pubmed | 7.23e-06 | 2 | 94 | 2 | 20581824 | ||
| Pubmed | Circadian regulation of Tshb gene expression by Rev-Erbα (NR1D1) and nuclear corepressor 1 (NCOR1). | 7.23e-06 | 2 | 94 | 2 | 24794873 | |
| Pubmed | 7.23e-06 | 2 | 94 | 2 | 23706170 | ||
| Pubmed | Integrative modeling defines the Nova splicing-regulatory network and its combinatorial controls. | 7.23e-06 | 2 | 94 | 2 | 20558669 | |
| Pubmed | 7.23e-06 | 2 | 94 | 2 | 17065982 | ||
| Pubmed | 7.23e-06 | 2 | 94 | 2 | 14615540 | ||
| Pubmed | HITS-CLIP yields genome-wide insights into brain alternative RNA processing. | 7.23e-06 | 2 | 94 | 2 | 18978773 | |
| Pubmed | Nova regulates brain-specific splicing to shape the synapse. | 7.23e-06 | 2 | 94 | 2 | 16041372 | |
| Pubmed | 7.23e-06 | 2 | 94 | 2 | 19940123 | ||
| Pubmed | Deubiquitinating enzymes: a new class of biological regulators. | 8.50e-06 | 15 | 94 | 3 | 9827704 | |
| Pubmed | Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. | 8.50e-06 | 15 | 94 | 3 | 11092755 | |
| Pubmed | A strategy for modulation of enzymes in the ubiquitin system. | 1.26e-05 | 17 | 94 | 3 | 23287719 | |
| Pubmed | NCOR1 NF1 RPLP2 WDR11 UBR5 LNPEP USP9X IGHMBP2 PSMB2 NCAPD2 MED1 ITGAL BRAT1 | 1.57e-05 | 1168 | 94 | 13 | 19946888 | |
| Pubmed | Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function. | NF1 LMNA RPLP2 WDR11 UBR5 PLEKHG4 POLA1 PSMB2 NUMA1 NCAPD2 ANKHD1 ADNP USP16 DDB1 | 1.62e-05 | 1353 | 94 | 14 | 29467282 |
| Pubmed | 1.80e-05 | 19 | 94 | 3 | 17392787 | ||
| Pubmed | Cooperative cobinding of synthetic and natural ligands to the nuclear receptor PPARγ. | 2.16e-05 | 3 | 94 | 2 | 30575522 | |
| Pubmed | 2.16e-05 | 3 | 94 | 2 | 19147702 | ||
| Pubmed | 2.16e-05 | 3 | 94 | 2 | 8657146 | ||
| Pubmed | 2.16e-05 | 3 | 94 | 2 | 8561800 | ||
| Pubmed | Analysis of Ah receptor-ARNT and Ah receptor-ARNT2 complexes in vitro and in cell culture. | 2.16e-05 | 3 | 94 | 2 | 18096572 | |
| Pubmed | MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53. | 2.16e-05 | 3 | 94 | 2 | 34716260 | |
| Pubmed | 2.16e-05 | 3 | 94 | 2 | 19838211 | ||
| Pubmed | Expression of Arnt and Arnt2 mRNA in developing murine tissues. | 2.16e-05 | 3 | 94 | 2 | 12502753 | |
| Pubmed | 2.16e-05 | 3 | 94 | 2 | 15761026 | ||
| Pubmed | 2.16e-05 | 3 | 94 | 2 | 35296664 | ||
| Pubmed | 2.16e-05 | 3 | 94 | 2 | 29291617 | ||
| Pubmed | 2.16e-05 | 3 | 94 | 2 | 36343253 | ||
| Pubmed | MDM2 and MDMX bind and stabilize the p53-related protein p73. | 2.16e-05 | 3 | 94 | 2 | 10469568 | |
| Pubmed | 2.16e-05 | 3 | 94 | 2 | 24814368 | ||
| Pubmed | Aberrant methylation of tumour suppressor genes WT1, GATA5 and PAX5 in hepatocellular carcinoma. | 2.16e-05 | 3 | 94 | 2 | 27171388 | |
| Pubmed | 2.16e-05 | 3 | 94 | 2 | 8948627 | ||
| Pubmed | 2.16e-05 | 3 | 94 | 2 | 9482666 | ||
| Pubmed | 2.16e-05 | 3 | 94 | 2 | 20160030 | ||
| Pubmed | 2.26e-05 | 124 | 94 | 5 | 35516420 | ||
| Pubmed | 2.36e-05 | 210 | 94 | 6 | 16565220 | ||
| Pubmed | An atlas of combinatorial transcriptional regulation in mouse and man. | 2.53e-05 | 877 | 94 | 11 | 20211142 | |
| Pubmed | Photocaged Cell-Permeable Ubiquitin Probe for Temporal Profiling of Deubiquitinating Enzymes. | 2.81e-05 | 64 | 94 | 4 | 33141564 | |
| Pubmed | 2.92e-05 | 446 | 94 | 8 | 24255178 | ||
| Pubmed | The Tumor Suppressor CIC Directly Regulates MAPK Pathway Genes via Histone Deacetylation. | 2.95e-05 | 583 | 94 | 9 | 29844126 | |
| Pubmed | NCOR1 ABLIM1 ARNT LMNA MYO5B RPLP2 IGHMBP2 PSMB2 NUMA1 MED1 DDB1 LANCL2 LRRFIP2 | 3.10e-05 | 1247 | 94 | 13 | 27684187 | |
| Pubmed | Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. | 3.10e-05 | 327 | 94 | 7 | 15592455 | |
| Pubmed | Comprehensive identification of phosphorylation sites in postsynaptic density preparations. | 4.02e-05 | 231 | 94 | 6 | 16452087 | |
| Pubmed | Menin and Menin-Associated Proteins Coregulate Cancer Energy Metabolism. | 4.04e-05 | 341 | 94 | 7 | 32971831 | |
| Pubmed | The alternative splicing factor Nova2 regulates vascular development and lumen formation. | 4.32e-05 | 4 | 94 | 2 | 26446569 | |
| Pubmed | 4.32e-05 | 4 | 94 | 2 | 1680807 | ||
| Pubmed | 4.32e-05 | 4 | 94 | 2 | 24445145 | ||
| Pubmed | 4.32e-05 | 4 | 94 | 2 | 33168788 | ||
| Pubmed | 4.32e-05 | 4 | 94 | 2 | 30603043 | ||
| Pubmed | Associations between oxytocin-related genes and autistic-like traits. | 4.32e-05 | 4 | 94 | 2 | 24635660 | |
| Pubmed | WT1, MSH6, GATA5 and PAX5 as epigenetic oral squamous cell carcinoma biomarkers - a short report. | 4.32e-05 | 4 | 94 | 2 | 27491556 | |
| Pubmed | β(2) integrins inhibit TLR responses by regulating NF-κB pathway and p38 MAPK activation. | 4.32e-05 | 4 | 94 | 2 | 23310953 | |
| Pubmed | 4.32e-05 | 4 | 94 | 2 | 26490262 | ||
| Pubmed | NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma. | 4.32e-05 | 4 | 94 | 2 | 23318450 | |
| Pubmed | Physical interaction between Wilms tumor 1 and p73 proteins modulates their functions. | 4.32e-05 | 4 | 94 | 2 | 10744705 | |
| Pubmed | Large-scale characterization of HeLa cell nuclear phosphoproteins. | NCOR1 ABLIM1 SCML2 NF1 LMNA NUMA1 MED1 NR1D1 USP16 CTTNBP2NL | 4.73e-05 | 774 | 94 | 10 | 15302935 |
| Pubmed | 4.95e-05 | 146 | 94 | 5 | 29688375 | ||
| Pubmed | NOVA-dependent regulation of cryptic NMD exons controls synaptic protein levels after seizure. | 5.34e-05 | 27 | 94 | 3 | 23359859 | |
| Pubmed | Compartmentalization of the SUMO/RNF4 pathway by SLX4 drives DNA repair. | 5.39e-05 | 357 | 94 | 7 | 37059091 | |
| Pubmed | NCOR1 ABLIM1 NF1 UBR5 USP9X NUMA1 BSN ADNP UNC79 DDB1 LRRFIP2 | 5.90e-05 | 963 | 94 | 11 | 28671696 | |
| Pubmed | 6.44e-05 | 79 | 94 | 4 | 27325702 | ||
| Pubmed | 6.76e-05 | 80 | 94 | 4 | 28205554 | ||
| Pubmed | 7.19e-05 | 5 | 94 | 2 | 19221030 | ||
| Pubmed | 7.19e-05 | 5 | 94 | 2 | 27721409 | ||
| Pubmed | Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73. | 7.19e-05 | 5 | 94 | 2 | 21088494 | |
| Pubmed | 7.19e-05 | 5 | 94 | 2 | 35178390 | ||
| Pubmed | CRL4(VprBP) E3 ligase promotes monoubiquitylation and chromatin binding of TET dioxygenases. | 7.19e-05 | 5 | 94 | 2 | 25557551 | |
| Pubmed | Expression of ARNT, ARNT2, HIF1 alpha, HIF2 alpha and Ah receptor mRNAs in the developing mouse. | 7.19e-05 | 5 | 94 | 2 | 9545558 | |
| Pubmed | 7.19e-05 | 5 | 94 | 2 | 9020169 | ||
| Pubmed | HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP E3 ligase complex. | 7.19e-05 | 5 | 94 | 2 | 23612978 | |
| Interaction | SIM1 interactions | 5.24e-06 | 8 | 93 | 3 | int:SIM1 | |
| Interaction | HAPSTR1 interactions | ABLIM1 ARNT NF1 WDR11 UBR5 USP9X NCAPD2 BSN ANKHD1 MDM4 ADNP CBLB DDB1 LANCL2 DOP1B | 5.63e-06 | 829 | 93 | 15 | int:HAPSTR1 |
| Interaction | SIRT6 interactions | NF1 LMNA RPLP2 UBR5 USP9X NUMA1 NCAPD2 CCSER2 MED1 ADNP PCDHGC3 DDB1 MNAT1 | 6.08e-06 | 628 | 93 | 13 | int:SIRT6 |
| Interaction | PML interactions | TET2 NCOR1 USP2 ABLIM1 ARNT NF1 LMNA UBR5 HIPK1 NUMA1 MED1 CDH19 BRAT1 CTTNBP2NL TP73 | 2.28e-05 | 933 | 93 | 15 | int:PML |
| Interaction | ZCCHC14 interactions | 2.50e-05 | 37 | 93 | 4 | int:ZCCHC14 | |
| Interaction | WWTR1 interactions | NCOR1 ABLIM1 ARNT SCML2 ARNT2 NUMA1 NCAPD2 PEAK1 ANKHD1 ADNP | 2.50e-05 | 422 | 93 | 10 | int:WWTR1 |
| Interaction | RNF6 interactions | 2.68e-05 | 76 | 93 | 5 | int:RNF6 | |
| Interaction | YAP1 interactions | NCOR1 ABLIM1 ARNT SCML2 NF1 LMNA USP9X ARNT2 NUMA1 WT1 GLIS3 IGSF9B MED1 ADNP NR1D1 TP73 | 3.78e-05 | 1095 | 93 | 16 | int:YAP1 |
| Interaction | MATR3 interactions | NCOR1 ARNT LMNA UBR5 PLEKHG4 RBM4B USP9X NUMA1 NCAPD2 DDB1 NOVA1 NOVA2 | 4.72e-05 | 655 | 93 | 12 | int:MATR3 |
| Interaction | TFAP2D interactions | 5.74e-05 | 89 | 93 | 5 | int:TFAP2D | |
| Interaction | ERG interactions | 7.82e-05 | 223 | 93 | 7 | int:ERG | |
| Interaction | BTNL2 interactions | 8.25e-05 | 155 | 93 | 6 | int:BTNL2 | |
| ToppCell | Bronchial-NucSeq-Endothelial-Endothelia_vascular-VE_pulmonary_venous|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.20e-07 | 199 | 94 | 7 | 3a4deea6e11a0555d27497b7c9983350797aac69 | |
| ToppCell | Children_(3_yrs)-Endothelial-endothelial_cell_of_vein|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.86e-06 | 187 | 94 | 6 | e35716f8b482be3bf5ab79f087a9caf67a9d197a | |
| ToppCell | RA-04._Ventricular_Cardiomyocyte_I|World / Chamber and Cluster_Paper | 4.58e-06 | 115 | 94 | 5 | 0a37816898eaa18ae49d4d936e1a760f089e0ceb | |
| ToppCell | Parenchymal-10x3prime_v2-Stromal-Peri/Epineurial_-NAF_endoneurial|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 1.41e-05 | 145 | 94 | 5 | e808502fa52baf1c400f3c9b918a167127e78af9 | |
| ToppCell | E16.5-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK-NK-NK_mature|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.27e-05 | 160 | 94 | 5 | b2d8940ea8c068273b7da1589d3d6ae5110d8209 | |
| ToppCell | E16.5-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.27e-05 | 160 | 94 | 5 | 9caab1bb63c7e66c44783852ee75b16bb40fa594 | |
| ToppCell | E16.5-Immune-Immune_Lymphocytic_T/NK|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.27e-05 | 160 | 94 | 5 | 229841be7b984a00a301cd5d88c11226a90d8a88 | |
| ToppCell | E16.5-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK-NK|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.27e-05 | 160 | 94 | 5 | 99c9ae2041445539fada842e1af01368669bfca0 | |
| ToppCell | facs-Pancreas-Exocrine-3m-Epithelial-pancreatic_B_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.39e-05 | 174 | 94 | 5 | f1fe1f4216748a9562dd03bd48c70b23c7ff4d1d | |
| ToppCell | NS-moderate-d_07-13-Lymphoid-NK|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 3.49e-05 | 175 | 94 | 5 | f6cd24d22f62469319f9d244e3e5de527d3d4d94 | |
| ToppCell | COVID-19-Heart-EC_2|COVID-19 / Disease (COVID-19 only), tissue and cell type | 3.89e-05 | 179 | 94 | 5 | 2a53d94f6c30bf887dfe88f1693ea057218c852d | |
| ToppCell | Control-Endothelial_cells-Pulmonary_venous_endothelial_cells|Control / group, cell type (main and fine annotations) | 4.32e-05 | 183 | 94 | 5 | 46be9f96755c7b65aeac061d95d15abeb6466034 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5-6_PVALB_FAM150B|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.43e-05 | 184 | 94 | 5 | 7d41784eac0935e77d6bc701f20c693adf998730 | |
| ToppCell | CV-Healthy-7|Healthy / Virus stimulation, Condition and Cluster | 4.54e-05 | 185 | 94 | 5 | 1979d189c204f4c2893e3170a514ee7d5523406c | |
| ToppCell | Children_(3_yrs)-Endothelial-endothelial_cell_of_artery-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 4.54e-05 | 185 | 94 | 5 | a7ae76058b2082020cadec49d63b9f4e24d21734 | |
| ToppCell | COVID-19-Endothelial_cells-Pulmonary_venous_endothelial_cells|COVID-19 / group, cell type (main and fine annotations) | 4.78e-05 | 187 | 94 | 5 | 2d20193a6cacdfa4877457c97b0077408942186c | |
| ToppCell | 10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8|GI_small-bowel / Manually curated celltypes from each tissue | 4.91e-05 | 188 | 94 | 5 | ab9b725d6e0cdab8e9ddda6dee09e14730e9a578 | |
| ToppCell | COVID-19-lung-Artery_EC|lung / Disease (COVID-19 only), tissue and cell type | 4.91e-05 | 188 | 94 | 5 | eecd7482b3c97d7f49993cb17edfab30c61232fc | |
| ToppCell | Children_(3_yrs)-Endothelial-capillary_endothelial_cell_(Cap1)-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 4.91e-05 | 188 | 94 | 5 | 117dc80fa940e6aa1b0187a43fdde33f3fcb578f | |
| ToppCell | Fetal_29-31_weeks-Epithelial-lung_neuroendocrine_cell_(PNEC)-D150|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 4.91e-05 | 188 | 94 | 5 | c4c3b21ab723b0e9beff9ec84f8d68485f771528 | |
| ToppCell | Endothelial-endothelial_cell_of_artery|World / Lineage, Cell type, age group and donor | 5.03e-05 | 189 | 94 | 5 | fdd89c71113ac99b7c800c6def8888e512ff1128 | |
| ToppCell | CD8+_Memory_T_cell-CV-7|CD8+_Memory_T_cell / cell class, Virus stimulation and cluster | 5.29e-05 | 191 | 94 | 5 | 9454f642c3621370fa23640b631301346b300950 | |
| ToppCell | 10x5'-lymph-node_spleen-Lymphocytic_T_CD4-T_CD4/CD8|lymph-node_spleen / Manually curated celltypes from each tissue | 5.42e-05 | 192 | 94 | 5 | 47646d7e4990be85072987f92bf18d52f8da752e | |
| ToppCell | facs-Marrow-KLS-18m-Myeloid-granulocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.42e-05 | 192 | 94 | 5 | be75783d9578974b662e1cb13bd3442a921fd50a | |
| ToppCell | facs-Marrow-KLS-18m-Myeloid-granulocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.42e-05 | 192 | 94 | 5 | 4fc98f30f8e738816cd93101fbe8ac40889e302a | |
| ToppCell | LA-14._Fibroblast_III|LA / Chamber and Cluster_Paper | 5.56e-05 | 193 | 94 | 5 | 7426c291bac59e539c427bcaae18abc7d397d44e | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c02-GPR183|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.56e-05 | 193 | 94 | 5 | c3cffafc1d40c3d7cf81034d5c51f1c78f5eb0a9 | |
| ToppCell | droplet-Lung-LUNG-1m-Myeloid-Proliferating_Alveolar_Macrophage|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.69e-05 | 194 | 94 | 5 | effd38e51062b225ecabc7e1c50154e65495d559 | |
| ToppCell | LA-14._Fibroblast_III|World / Chamber and Cluster_Paper | 5.69e-05 | 194 | 94 | 5 | 803fa83ceada17c38ca9f933b888f7e7b0b90761 | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 5.83e-05 | 195 | 94 | 5 | c5d2d9f12fd893331c9de261af30607d845d4f6a | |
| ToppCell | Bronchial-NucSeq-Endothelial-Endothelia_vascular-VE_systemic_venous|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 5.83e-05 | 195 | 94 | 5 | fde8e7b38b3631109b95ef111c5f6e3f9878cfbd | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.83e-05 | 195 | 94 | 5 | ed5f772c82d4dfd1c8735224446ec9feae3fb8c2 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 5.98e-05 | 196 | 94 | 5 | 6ce74aa3f0ce3ca284b67e5a4660ffd2cc9611e0 | |
| ToppCell | COVID-19-lung-Capillary_1|lung / Disease (COVID-19 only), tissue and cell type | 6.12e-05 | 197 | 94 | 5 | 7e86ff9dafcbaaa7464d61484dd48bfeb7eae6e4 | |
| ToppCell | Bronchial-NucSeq-Stromal-Peri/Epineurial_|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 6.12e-05 | 197 | 94 | 5 | ee8f7def9d5af7b1e636830a4ea1da158d02f25a | |
| ToppCell | Sepsis-Bac-SEP-Lymphocyte-T/NK-CD8+_T_naive|Bac-SEP / Disease, condition lineage and cell class | 6.27e-05 | 198 | 94 | 5 | a9a009e5eeb935232034635ad4a3c27d83c081ac | |
| ToppCell | Tracheal-NucSeq-Epithelial-Epi_submucosal-gland-SMG_Mucous|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 6.58e-05 | 200 | 94 | 5 | c450a15e21fa72d071ed6e3b9f22de557a0f3cea | |
| ToppCell | Tracheal-NucSeq-Epithelial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 6.58e-05 | 200 | 94 | 5 | d3af0a706baf66e3f32e67b17dcfc31e5b32ce0e | |
| ToppCell | COVID-19-kidney-Lymphatic_EC|COVID-19 / Disease (COVID-19 only), tissue and cell type | 2.72e-04 | 148 | 94 | 4 | f777aa1674e898e2594b2b7c029d3d05dda04df9 | |
| ToppCell | TCGA-Breast-Primary_Tumor-Breast_Carcinoma-Mucinous_Carcinoma-1|TCGA-Breast / Sample_Type by Project: Shred V9 | 2.80e-04 | 149 | 94 | 4 | 649eb3441fa859591ea85f1ed5fcf08af272a32b | |
| ToppCell | Adult-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D175|Adult / Lineage, Cell type, age group and donor | 2.87e-04 | 150 | 94 | 4 | b0b6ba3686d3eb8a9b249d30be14111de3b893be | |
| ToppCell | URO-Lymphocyte-T_NK-CD4_Naive|URO / Disease, Lineage and Cell Type | 3.17e-04 | 154 | 94 | 4 | 6c214ad5cbbfa8bab3f76b593cb598dfb914b566 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-high_Fibroblast|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 3.25e-04 | 155 | 94 | 4 | 82e602f31981c6b48abff2a04b2ab5d26d4462a2 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-OPC-OPC-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.25e-04 | 155 | 94 | 4 | 77fdae85d36efb776db977eb424b32487ef222e4 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-high_Fibroblast-|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 3.25e-04 | 155 | 94 | 4 | 979c1d53b435a82c57d16707eed8ba7346326866 | |
| ToppCell | TCGA-Lung-Primary_Tumor-Lung_Carcinoma-Lung_Adenocarcinoma_Mixed_Subtype-2|TCGA-Lung / Sample_Type by Project: Shred V9 | 3.49e-04 | 158 | 94 | 4 | 9dea15b28f64206bac0e785df6f36a2cc9010ac7 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Glomerular_Capillary_Endothelial_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 3.58e-04 | 159 | 94 | 4 | d3f81ba22160568ccaa6d2b04ebfd30630f9a6db | |
| ToppCell | Bronchial-10x5prime-Stromal-Myofibroblastic-Muscle_smooth_airway_ASM|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 3.58e-04 | 159 | 94 | 4 | 7cda111bb98f1241989e49d490bdf51a712ea589 | |
| ToppCell | Hippocampus-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 3.75e-04 | 161 | 94 | 4 | b81b346309f3facbfbebd91cae4c5b33c7bd24ef | |
| ToppCell | Brain_organoid-organoid_Velasco_nature-3_mon-Neuronal-Cajal-Retzius|3_mon / Sample Type, Dataset, Time_group, and Cell type. | 3.84e-04 | 162 | 94 | 4 | 1f589a763f3fd4e1e612809ef3903879d47dc1d8 | |
| ToppCell | 10x5'-blood-Lymphocytic_T_CD4-T_CD4/CD8|blood / Manually curated celltypes from each tissue | 3.84e-04 | 162 | 94 | 4 | b4535bcb3f469bc139e73f1122f4070013e5a1de | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum-3m-Epithelial-neuronal_stem_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.11e-04 | 165 | 94 | 4 | 1703d3eb644b3c743ad3c5532b1d29ea010c79c8 | |
| ToppCell | LPS-antiTNF-Epithelial_airway|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.21e-04 | 166 | 94 | 4 | eb942ed68677e55c46cb039046f45686d4062d7c | |
| ToppCell | LPS-antiTNF-Epithelial_airway-Club_cells|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.21e-04 | 166 | 94 | 4 | 1df4bdf7c773cbfa6c93d7a901f9cd3f3fe07a3d | |
| ToppCell | LPS-antiTNF-Epithelial_airway-Club_cells-Airway|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.21e-04 | 166 | 94 | 4 | 9628522e7af8f8edca733588a364ab2454ac5ca5 | |
| ToppCell | LPS-antiTNF-Endothelial-Mes-Like-Alv_Cap|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.21e-04 | 166 | 94 | 4 | 94a00edf66d54bc5f7343daea700ca26cf38fd90 | |
| ToppCell | Cerebellum-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)|Cerebellum / BrainAtlas - Mouse McCarroll V32 | 4.31e-04 | 167 | 94 | 4 | 9efb9511a211d0824bb97f82c1a5860c43d2138f | |
| ToppCell | droplet-Trachea-3m-Mesenchymal-fibroblast-fibroblast_of_trachea-|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.31e-04 | 167 | 94 | 4 | 774f3264318b002d0df5d06d41d645366038d0bf | |
| ToppCell | Cerebellum-Neuronal-Inhibitory|Cerebellum / BrainAtlas - Mouse McCarroll V32 | 4.31e-04 | 167 | 94 | 4 | 904c613aac3f9919a432b110bb1dcc832b5aec0a | |
| ToppCell | Control|World / group, cell type (main and fine annotations) | 4.40e-04 | 168 | 94 | 4 | a3511faf2cd2c2b9c8363c8b99da3f3609c43ed6 | |
| ToppCell | 10x5'-lymph-node_spleen-Lymphocytic_B-ABC_aged-B_naive|lymph-node_spleen / Manually curated celltypes from each tissue | 4.40e-04 | 168 | 94 | 4 | 494d5a11154ff22fedb25f4036d730cef376da60 | |
| ToppCell | 5'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.50e-04 | 169 | 94 | 4 | 8bca402e144819cb9a8d431d6bf9429be2fff6d6 | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_airway-Club_cells|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.50e-04 | 169 | 94 | 4 | 8c96e1baa38ec5e777e627ab9dbce025e771f2c0 | |
| ToppCell | TCGA-Bladder-Primary_Tumor-Urothelial_Carcinoma-Non-Papillary_Muscle_Invasive_Urothelial_Carcinoma-5|TCGA-Bladder / Sample_Type by Project: Shred V9 | 4.50e-04 | 169 | 94 | 4 | 9c4e83fe8225d16173a103bf5a57b17d623be923 | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_airway-Club_cells-Airway|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.50e-04 | 169 | 94 | 4 | 86041be5d3aeab5b9269f7912791b944f325a1b4 | |
| ToppCell | facs-Diaphragm-Limb_Muscle-24m|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.50e-04 | 169 | 94 | 4 | 12bdc709bc000d7f9061ecd9fbd57233eaacb7e2 | |
| ToppCell | E16.5-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-AEC-AEC_prolif|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 4.60e-04 | 170 | 94 | 4 | 55fe16d98ea284d05fb899888e4569c685644c7b | |
| ToppCell | droplet-Lung-21m-Hematologic-lymphocytic-CD8-positive,_alpha-beta_T_cell-CD8-positive,_alpha-beta_T_cell_l48|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.60e-04 | 170 | 94 | 4 | 070d8683d1a5cc7d594ff0453c961a9bf982c2d0 | |
| ToppCell | Control-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.60e-04 | 170 | 94 | 4 | 5570c0e825bca77613bf0ebde620cf744fa1cb84 | |
| ToppCell | COVID-19_Convalescent-cDC|COVID-19_Convalescent / Disease condition and Cell class | 4.71e-04 | 171 | 94 | 4 | 9ccaa9f1629818b0f63a5d930ee78c01e04cd98d | |
| ToppCell | COVID-19_Convalescent-cDC-|COVID-19_Convalescent / Disease condition and Cell class | 4.71e-04 | 171 | 94 | 4 | fb5fae8b3adafcbb7c5618d887966b418355ed4d | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.81e-04 | 172 | 94 | 4 | 08a3fe536b1b064c5ee7779bc2b1115a5963a26b | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.81e-04 | 172 | 94 | 4 | 553701349444eb366df3c11f54bb093434f153c6 | |
| ToppCell | Fetal_29-31_weeks-Endothelial-endothelial_cell_of_artery-D062|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 4.81e-04 | 172 | 94 | 4 | de9b11ab109d04937186c09772cec9105a935f95 | |
| ToppCell | droplet-Heart-HEART-1m-Endothelial-leukocyte|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.92e-04 | 173 | 94 | 4 | 9dc7746a84f0e268a7c061e1bbcd5e31903034dc | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Glomerular_Capillary_Endothelial_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 4.92e-04 | 173 | 94 | 4 | afa6bb19df52541d8d17cbfac9cbdd18a5f3632d | |
| ToppCell | Mild/Remission-B_naive-8|World / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 4.92e-04 | 173 | 94 | 4 | 694d02c4d2dc2de4b344544f9124fec40fcf7d8f | |
| ToppCell | 3'-Child04-06-SmallIntestine-Epithelial-neuro-epithelial-EC_cells_(TAC1+)|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 5.03e-04 | 174 | 94 | 4 | a62531ebf16b32b249168dca11b870f63a8aa81c | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical-aged|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 5.13e-04 | 175 | 94 | 4 | 1b4cefae400bf756d09ece32d3f5c0bd4c6ad73f | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-kidney_interstitial_fibroblast_5|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 5.13e-04 | 175 | 94 | 4 | 910a075ccaf79de22338ecf321fa0a867f3d7d75 | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 5.13e-04 | 175 | 94 | 4 | 12f5fd83c7710fc0c77406f765d9cbd133433b8b | |
| ToppCell | Adult-Endothelial-endothelial_cell_of_artery-D175|Adult / Lineage, Cell type, age group and donor | 5.13e-04 | 175 | 94 | 4 | 0a65ddfa8c2e8efb5b5338cf07661cb78157a23c | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 5.13e-04 | 175 | 94 | 4 | f0c2eb82e17e8aec2cfa5d83169178f409cc1abc | |
| ToppCell | wk_08-11-Epithelial-Proximal_epithelial-SMG_basal_2|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 5.13e-04 | 175 | 94 | 4 | 4462000b22af227555413ba202a872868eecde6c | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5-6_PVALB_STON2|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.25e-04 | 176 | 94 | 4 | 682a1dfcc507ec540f5fadf08e872533ea9f0291 | |
| ToppCell | TCGA-Brain-Primary_Tumor-Low_Grade_Glioma|TCGA-Brain / Sample_Type by Project: Shred V9 | 5.36e-04 | 177 | 94 | 4 | e8ab340b20cd41554c3841fe980e078e878af35f | |
| ToppCell | normal-na-Lymphocytic_T-CD4-positive,_alpha-beta_T_cell-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 5.47e-04 | 178 | 94 | 4 | fa3585383a1e7da460c88a802aaa81246d681b6b | |
| ToppCell | PCW_13-14-Endothelial-Endothelial_mature-endo_arterial_(9)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 5.47e-04 | 178 | 94 | 4 | c227da59dc7beb73f84405bf13356bdeb59d9338 | |
| ToppCell | 3'-GW_trimst-1-SmallIntestine-Epithelial-epithelial_progenitor_cell-CLDN10+_cells|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 5.59e-04 | 179 | 94 | 4 | 7eca1e19ae6b5b1f18c721691dc3e860705628f2 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5-6_PVALB_STON2|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.59e-04 | 179 | 94 | 4 | d1365d48d1b017a7917f4f63a82ac4720c3d87df | |
| ToppCell | COVID-19-kidney-AQP1+SLC14A1+EC|COVID-19 / Disease (COVID-19 only), tissue and cell type | 5.59e-04 | 179 | 94 | 4 | 1ce8d18f63e8dd2d3db41fbeca4601bd3b305fba | |
| ToppCell | LA-01._Fibroblast_I|LA / Chamber and Cluster_Paper | 5.59e-04 | 179 | 94 | 4 | dcb6ec9ae72b13fe388b72dace2815293fafe8ee | |
| ToppCell | RSV-Healthy-0|RSV / Virus stimulation, Condition and Cluster | 5.71e-04 | 180 | 94 | 4 | 974044056e2f7e909cb11c6f6ca89e58bf95f7e5 | |
| ToppCell | Children_(3_yrs)-Epithelial-club_cell-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 5.71e-04 | 180 | 94 | 4 | b509c7d6bdfba672065fb722874bdc68de72ba1c | |
| ToppCell | RSV-Healthy-0|Healthy / Virus stimulation, Condition and Cluster | 5.71e-04 | 180 | 94 | 4 | 703a1d0f9536af94d56757eb01221878d7b7fe61 | |
| ToppCell | Children_(3_yrs)-Endothelial-endothelial_cell_of_vein-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 5.71e-04 | 180 | 94 | 4 | 27e8bbee388e64dd79d70b160b76d45b1f398006 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5-6_PVALB_FAM150B|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.83e-04 | 181 | 94 | 4 | af92b8b7f455210dab502ef6964f3a0162180759 | |
| ToppCell | COVID-19-Endothelial_cells-Endothelial_cells_(other)|COVID-19 / group, cell type (main and fine annotations) | 5.83e-04 | 181 | 94 | 4 | 26eb4ee57a70dbf54e096b73129fda9dfda1f6ec | |
| ToppCell | (2)_5-FU-(4)_COL2.3+_osteoblasts|(2)_5-FU / Stress and Cell class | 5.83e-04 | 181 | 94 | 4 | 56ae86072858c156681507aecd1bc6cb0a3372d2 | |
| ToppCell | TCGA-Colorectal-Solid_Tissue_Normal|TCGA-Colorectal / Sample_Type by Project: Shred V9 | 5.83e-04 | 181 | 94 | 4 | 88f6f56f5f58b479d5db91b32c45934c045f88ea | |
| Drug | Mesoridazine besylate [32672-69-8]; Down 200; 7.4uM; MCF7; HT_HG-U133A | 1.42e-06 | 196 | 93 | 8 | 7017_DN | |
| Drug | Hexetidine [141-94-6]; Down 200; 11.8uM; HL60; HT_HG-U133A | 1.48e-06 | 197 | 93 | 8 | 2457_DN | |
| Drug | 11-fluoro-7-(14,14,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3-5(10)-triene-3,17-diol | 5.44e-06 | 9 | 93 | 3 | ctd:C541120 | |
| Drug | Etanidazole [22668-01-5]; Down 200; 18.6uM; MCF7; HT_HG-U133A | 1.49e-05 | 194 | 93 | 7 | 6072_DN | |
| Drug | Cefsulodin sodium salt [52152-93-9]; Down 200; 7.2uM; MCF7; HT_HG-U133A | 1.60e-05 | 196 | 93 | 7 | 4148_DN | |
| Drug | Isopyrin hydrochloride [18342-39-7]; Down 200; 14.2uM; HL60; HT_HG-U133A | 1.60e-05 | 196 | 93 | 7 | 2534_DN | |
| Drug | Tocopherol (R,S) [10191-41-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A | 1.60e-05 | 196 | 93 | 7 | 3256_UP | |
| Drug | Tetracaone hydrochloride [136-47-0]; Down 200; 13.2uM; MCF7; HT_HG-U133A | 1.60e-05 | 196 | 93 | 7 | 2888_DN | |
| Drug | Rolitetracycline [751-97-3]; Up 200; 7.6uM; MCF7; HT_HG-U133A | 1.60e-05 | 196 | 93 | 7 | 3369_UP | |
| Drug | estradiol, USP; Up 200; 0.1uM; MCF7; HT_HG-U133A | 1.60e-05 | 196 | 93 | 7 | 6928_UP | |
| Drug | Evoxine [522-11-2]; Up 200; 11.6uM; PC3; HT_HG-U133A | 1.65e-05 | 197 | 93 | 7 | 3681_UP | |
| Drug | Sulfadimethoxine [122-11-2]; Down 200; 12.8uM; MCF7; HT_HG-U133A | 1.70e-05 | 198 | 93 | 7 | 3441_DN | |
| Drug | Ozagrel hydrochloride [78712-43-3]; Down 200; 15.2uM; MCF7; HT_HG-U133A | 1.70e-05 | 198 | 93 | 7 | 5983_DN | |
| Drug | estradiol, USP; Up 200; 0.01uM; PC3; HG-U133A | 1.70e-05 | 198 | 93 | 7 | 665_UP | |
| Drug | Acemetacin [53164-05-9]; Down 200; 9.6uM; MCF7; HT_HG-U133A | 1.70e-05 | 198 | 93 | 7 | 7442_DN | |
| Drug | Aceclofenac [89796-99-6]; Down 200; 11.2uM; MCF7; HT_HG-U133A | 1.70e-05 | 198 | 93 | 7 | 2281_DN | |
| Drug | hmimBF4 | 4.94e-05 | 3 | 93 | 2 | CID002734179 | |
| Drug | 1-octyl-3-methylimidazolium tetrafluoroborate | 4.94e-05 | 3 | 93 | 2 | CID011460221 | |
| Drug | bis(hexamethylene)triamine | 8.14e-05 | 56 | 93 | 4 | CID000008924 | |
| Drug | Adiphenine hydrochloride [50-42-0]; Down 200; 11.4uM; MCF7; HT_HG-U133A | 1.06e-04 | 183 | 93 | 6 | 1709_DN | |
| Drug | Ketanserin tartrate hydrate [83846-83-7]; Down 200; 7uM; PC3; HT_HG-U133A | 1.27e-04 | 189 | 93 | 6 | 6649_DN | |
| Drug | Fenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT_HG-U133A | 1.34e-04 | 191 | 93 | 6 | 4279_DN | |
| Drug | Scopolamine Hydrobromide | 1.34e-04 | 120 | 93 | 5 | ctd:D012601 | |
| Drug | estradiol, USP; Up 200; 0.01uM; MCF7; HT_HG-U133A | 1.38e-04 | 192 | 93 | 6 | 5238_UP | |
| Drug | CP-690334-01 [459212-38-5]; Down 200; 10uM; MCF7; HT_HG-U133A | 1.42e-04 | 193 | 93 | 6 | 3906_DN | |
| Drug | Nitrofural [59-87-0]; Down 200; 20.2uM; HL60; HT_HG-U133A | 1.42e-04 | 193 | 93 | 6 | 2459_DN | |
| Drug | GSK-3 Inhibitor IX; Up 200; 0.5uM; MCF7; HT_HG-U133A | 1.46e-04 | 194 | 93 | 6 | 6589_UP | |
| Drug | Ajmalicine hydrochloride [4373-34-6]; Down 200; 10.2uM; HL60; HG-U133A | 1.46e-04 | 194 | 93 | 6 | 1748_DN | |
| Drug | Norethynodrel [68-23-5]; Up 200; 13.4uM; HL60; HT_HG-U133A | 1.46e-04 | 194 | 93 | 6 | 1860_UP | |
| Drug | Beta-Escin [11072-93-8]; Down 200; 3.2uM; PC3; HT_HG-U133A | 1.46e-04 | 194 | 93 | 6 | 3807_DN | |
| Drug | Azaguanine-8 [134-58-7]; Down 200; 26.2uM; MCF7; HT_HG-U133A | 1.50e-04 | 195 | 93 | 6 | 7444_DN | |
| Drug | Sotalol hydrochloride [959-24-0]; Down 200; 13uM; HL60; HT_HG-U133A | 1.50e-04 | 195 | 93 | 6 | 2918_DN | |
| Drug | Cefamandole sodium salt [30034-03-8]; Up 200; 8.2uM; PC3; HT_HG-U133A | 1.50e-04 | 195 | 93 | 6 | 7394_UP | |
| Drug | haloperidol; Down 200; 10uM; HL60; HT_HG-U133A | 1.50e-04 | 195 | 93 | 6 | 6163_DN | |
| Drug | retinoic acid; Down 200; 1uM; MCF7; HT_HG-U133A | 1.50e-04 | 195 | 93 | 6 | 6971_DN | |
| Drug | Moroxidine hydrochloride [3160-91-6]; Down 200; 19.2uM; MCF7; HT_HG-U133A | 1.50e-04 | 195 | 93 | 6 | 1527_DN | |
| Drug | Progesterone [57-83-0]; Down 200; 12.8uM; MCF7; HT_HG-U133A | 1.50e-04 | 195 | 93 | 6 | 3287_DN | |
| Drug | Oxybutynin chloride [1508-65-2]; Down 200; 10.2uM; MCF7; HT_HG-U133A | 1.50e-04 | 195 | 93 | 6 | 6770_DN | |
| Drug | 2-propylpentanoic acid; Down 200; 1000uM; MCF7; HT_HG-U133A | 1.54e-04 | 196 | 93 | 6 | 5569_DN | |
| Drug | Timolol maleate salt [26921-17-5]; Down 200; 9.2uM; MCF7; HT_HG-U133A | 1.54e-04 | 196 | 93 | 6 | 5280_DN | |
| Drug | Prilocaine hydrochloride [1786-81-8]; Down 200; 15.6uM; MCF7; HT_HG-U133A | 1.54e-04 | 196 | 93 | 6 | 4749_DN | |
| Drug | pioglitazone HCl; Down 200; 10uM; MCF7; HT_HG-U133A | 1.54e-04 | 196 | 93 | 6 | 6898_DN | |
| Drug | Chrysene-1,4-quinone [100900-16-1]; Down 200; 15.4uM; PC3; HT_HG-U133A | 1.54e-04 | 196 | 93 | 6 | 7139_DN | |
| Drug | Naltrexone hydrochloride dihydrate [16676-29-2]; Down 200; 9.6uM; PC3; HT_HG-U133A | 1.54e-04 | 196 | 93 | 6 | 5765_DN | |
| Drug | Catechin-(+,-) hydrate [7295-85-4]; Down 200; 13.8uM; MCF7; HT_HG-U133A | 1.54e-04 | 196 | 93 | 6 | 3351_DN | |
| Drug | Methoxy-8-psoralen [298-81-7]; Down 200; 18.6uM; MCF7; HT_HG-U133A | 1.54e-04 | 196 | 93 | 6 | 3302_DN | |
| Drug | Pyrithyldione [77-04-3]; Down 200; 24uM; MCF7; HT_HG-U133A | 1.54e-04 | 196 | 93 | 6 | 3482_DN | |
| Drug | (-)-Cinchonidine [485-71-2]; Up 200; 13.6uM; PC3; HT_HG-U133A | 1.54e-04 | 196 | 93 | 6 | 5833_UP | |
| Drug | R(+)-verapamil hydrochloride; Up 200; 10uM; MCF7; HG-U133A | 1.54e-04 | 196 | 93 | 6 | 164_UP | |
| Drug | Nalbuphine hydrochloride [23277-43-2]; Down 200; 10.2uM; MCF7; HT_HG-U133A | 1.54e-04 | 196 | 93 | 6 | 2225_DN | |
| Drug | phenformin hydrochloride; Up 200; 10uM; MCF7; HG-U133A | 1.59e-04 | 197 | 93 | 6 | 21_UP | |
| Drug | Tiratricol, 3,3',5-triiodothyroacetic acid [51-24-1]; Down 200; 6.4uM; MCF7; HT_HG-U133A | 1.59e-04 | 197 | 93 | 6 | 7011_DN | |
| Drug | Trichlorfon [52-68-6]; Up 200; 15.6uM; MCF7; HT_HG-U133A | 1.59e-04 | 197 | 93 | 6 | 1675_UP | |
| Drug | 11-deoxy-16,16-dimethyl Prostaglandin E2; Up 200; 10uM; MCF7; HT_HG-U133A | 1.59e-04 | 197 | 93 | 6 | 7514_UP | |
| Drug | WY-14643; Down 200; 100uM; MCF7; HG-U133A | 1.59e-04 | 197 | 93 | 6 | 487_DN | |
| Drug | Clozapine [5786-21-0]; Up 200; 12.2uM; MCF7; HT_HG-U133A | 1.59e-04 | 197 | 93 | 6 | 5630_UP | |
| Drug | Zoxazolamine [61-80-3]; Down 200; 23.8uM; MCF7; HT_HG-U133A | 1.63e-04 | 198 | 93 | 6 | 5390_DN | |
| Drug | Ceftazidime pentahydrate [78439-06-2]; Down 200; 6.2uM; HL60; HG-U133A | 1.63e-04 | 198 | 93 | 6 | 1721_DN | |
| Drug | Amoxapine [14028-44-5]; Down 200; 12.8uM; MCF7; HT_HG-U133A | 1.63e-04 | 198 | 93 | 6 | 1513_DN | |
| Drug | Guaifenesin [93-14-1]; Down 200; 20.2uM; MCF7; HT_HG-U133A | 1.63e-04 | 198 | 93 | 6 | 3897_DN | |
| Drug | Epitiostanol [2363-58-8]; Down 200; 13uM; MCF7; HT_HG-U133A | 1.63e-04 | 198 | 93 | 6 | 4788_DN | |
| Drug | pioglitazone HCl; Down 200; 10uM; MCF7; HT_HG-U133A | 1.63e-04 | 198 | 93 | 6 | 5972_DN | |
| Drug | Isoxicam [34552-84-6]; Down 200; 12uM; MCF7; HT_HG-U133A | 1.63e-04 | 198 | 93 | 6 | 7028_DN | |
| Drug | Cefotiam hydrochloride; Down 200; 7.2uM; HL60; HT_HG-U133A | 1.63e-04 | 198 | 93 | 6 | 2458_DN | |
| Drug | Kynurenine, 3-hydroxy (R,S) [2147-61-7]; Up 200; 17.8uM; PC3; HT_HG-U133A | 1.63e-04 | 198 | 93 | 6 | 4681_UP | |
| Drug | Nitrocaramiphen hydrochloride; Down 200; 10.8uM; MCF7; HT_HG-U133A | 1.63e-04 | 198 | 93 | 6 | 7464_DN | |
| Drug | Nifenazone [2139-47-1]; Up 200; 13uM; MCF7; HT_HG-U133A | 1.63e-04 | 198 | 93 | 6 | 2285_UP | |
| Drug | Fenspiride hydrochloride [5053-08-7]; Down 200; 13.4uM; MCF7; HT_HG-U133A | 1.63e-04 | 198 | 93 | 6 | 6001_DN | |
| Drug | Dantrolene sodium salt [14663-23-1]; Up 200; 11.8uM; HL60; HT_HG-U133A | 1.63e-04 | 198 | 93 | 6 | 2369_UP | |
| Drug | Propidium iodide [25535-16-4]; Down 200; 6uM; HL60; HT_HG-U133A | 1.63e-04 | 198 | 93 | 6 | 2541_DN | |
| Drug | beta-hydroxyisovaleric acid | 1.64e-04 | 5 | 93 | 2 | ctd:C004961 | |
| Drug | emimBF4 | 1.64e-04 | 5 | 93 | 2 | CID002769348 | |
| Drug | 1,1-dimethylbiguanide hydrochloride; Down 200; 1000uM; MCF7; HG-U133A | 1.68e-04 | 199 | 93 | 6 | 4_DN | |
| Drug | Methapyrilene hydrochloride [135-23-9]; Down 200; 13.4uM; MCF7; HT_HG-U133A | 1.68e-04 | 199 | 93 | 6 | 3205_DN | |
| Drug | Leucomisine [17946-87-1]; Up 200; 16.2uM; MCF7; HT_HG-U133A | 1.68e-04 | 199 | 93 | 6 | 3546_UP | |
| Drug | tamoxifen citrate; Up 200; 1uM; MCF7; HG-U133A | 1.68e-04 | 199 | 93 | 6 | 143_UP | |
| Drug | Phenindione [83-12-5]; Down 200; 18uM; HL60; HG-U133A | 1.68e-04 | 199 | 93 | 6 | 1718_DN | |
| Drug | Neomycin sulfate [1405-10-3]; Down 200; 4.2uM; HL60; HG-U133A | 1.68e-04 | 199 | 93 | 6 | 1383_DN | |
| Drug | Cefuroxime sodium salt [56238-63-2]; Down 200; 9uM; MCF7; HT_HG-U133A | 1.68e-04 | 199 | 93 | 6 | 6088_DN | |
| Drug | Isoetharine mesylate salt [7279-75-6]; Up 200; 12uM; MCF7; HT_HG-U133A | 1.72e-04 | 200 | 93 | 6 | 7170_UP | |
| Drug | Diphemanil methylsulfate [62-97-5]; Down 200; 10.2uM; HL60; HG-U133A | 1.72e-04 | 200 | 93 | 6 | 1994_DN | |
| Drug | PeCDD | 1.80e-04 | 27 | 93 | 3 | CID000038439 | |
| Drug | MCDF | 2.01e-04 | 28 | 93 | 3 | CID000114900 | |
| Drug | 5EtdUTP | 2.45e-04 | 6 | 93 | 2 | CID000188305 | |
| Disease | nephroblastoma (is_implicated_in) | 1.04e-05 | 14 | 92 | 3 | DOID:2154 (is_implicated_in) | |
| Disease | Acute Promyelocytic Leukemia | 1.31e-05 | 46 | 92 | 4 | C0023487 | |
| Disease | Schwannomatosis, Plexiform | 9.56e-05 | 5 | 92 | 2 | C0751374 | |
| Disease | Glioblastoma | 1.11e-04 | 79 | 92 | 4 | C0017636 | |
| Disease | Giant Cell Glioblastoma | 1.41e-04 | 84 | 92 | 4 | C0334588 | |
| Disease | Neurilemmoma | 1.43e-04 | 6 | 92 | 2 | C0027809 | |
| Disease | autosomal recessive intellectual developmental disorder (implicated_via_orthology) | 2.66e-04 | 8 | 92 | 2 | DOID:0060308 (implicated_via_orthology) | |
| Disease | disorder of pharynx | 4.04e-04 | 46 | 92 | 3 | MONDO_0020592 | |
| Disease | Glioblastoma Multiforme | 4.11e-04 | 111 | 92 | 4 | C1621958 | |
| Disease | prostate carcinoma | 4.62e-04 | 891 | 92 | 10 | EFO_0001663 | |
| Disease | insomnia measurement | 4.80e-04 | 443 | 92 | 7 | EFO_0007876 | |
| Disease | complement C1q tumor necrosis factor-related protein 5 measurement | 5.19e-04 | 11 | 92 | 2 | EFO_0801494 | |
| Disease | corneal resistance factor | 5.33e-04 | 451 | 92 | 7 | EFO_0010067 | |
| Disease | Emery-Dreifuss muscular dystrophy (implicated_via_orthology) | 6.22e-04 | 12 | 92 | 2 | DOID:11726 (implicated_via_orthology) | |
| Disease | forced expiratory volume | 8.02e-04 | 789 | 92 | 9 | EFO_0004314 | |
| Disease | serum non-albumin protein measurement | 9.48e-04 | 361 | 92 | 6 | EFO_0004568 | |
| Disease | osteoarthritis, hip, osteoarthritis, knee | 9.71e-04 | 62 | 92 | 3 | EFO_0004616, EFO_1000786 | |
| Disease | periprosthetic osteolysis, disease progression measurement | 9.83e-04 | 15 | 92 | 2 | EFO_0008336, EFO_0009761 | |
| Disease | Mammary Carcinoma, Human | 1.29e-03 | 525 | 92 | 7 | C4704874 | |
| Disease | Mammary Neoplasms, Human | 1.29e-03 | 525 | 92 | 7 | C1257931 | |
| Disease | Mammary Neoplasms | 1.32e-03 | 527 | 92 | 7 | C1458155 | |
| Disease | renal cell carcinoma (is_implicated_in) | 1.32e-03 | 69 | 92 | 3 | DOID:4450 (is_implicated_in) | |
| Disease | Carcinoma of bladder | 1.42e-03 | 18 | 92 | 2 | C0699885 | |
| Disease | Breast Carcinoma | 1.49e-03 | 538 | 92 | 7 | C0678222 | |
| Disease | Endometrioma | 1.64e-03 | 161 | 92 | 4 | C0269102 | |
| Disease | Endometriosis | 1.64e-03 | 161 | 92 | 4 | C0014175 | |
| Disease | neuroimaging measurement | 1.83e-03 | 1069 | 92 | 10 | EFO_0004346 | |
| Disease | Sarcoma | 1.94e-03 | 21 | 92 | 2 | C1261473 | |
| Disease | polycystic ovary syndrome (biomarker_via_orthology) | 1.94e-03 | 21 | 92 | 2 | DOID:11612 (biomarker_via_orthology) | |
| Disease | otitis media (implicated_via_orthology) | 2.13e-03 | 22 | 92 | 2 | DOID:10754 (implicated_via_orthology) | |
| Disease | Leukemia, Myelocytic, Acute | 2.14e-03 | 173 | 92 | 4 | C0023467 | |
| Disease | thyroxine measurement | 2.25e-03 | 83 | 92 | 3 | EFO_0005130 | |
| Disease | serum iron measurement | 2.49e-03 | 86 | 92 | 3 | EFO_0006332 | |
| Disease | smoking status measurement, chronic obstructive pulmonary disease | 2.66e-03 | 88 | 92 | 3 | EFO_0000341, EFO_0006527 | |
| Disease | breast cancer (is_marker_for) | 2.72e-03 | 185 | 92 | 4 | DOID:1612 (is_marker_for) | |
| Disease | Kallmann Syndrome | 2.98e-03 | 26 | 92 | 2 | C0162809 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| GIYPASTQLDRNSLS | 251 | Q96P26 | |
| YTSEDLTSSSRPNGN | 891 | P51826 | |
| SQAPARYSLQSANAS | 386 | Q9H2P0 | |
| AAAYPSLTNRGSNFA | 691 | P27540 | |
| SSPFGTDYRNLANTA | 526 | Q9P2B4 | |
| ASYSSLREARGSPNT | 731 | Q6PJG6 | |
| SSRSYLALPGNSGED | 376 | Q9BZ76 | |
| QASEPYLRVANGSSL | 1121 | Q6UVK1 | |
| RASSSAGTDPQLLLY | 1606 | Q6UVK1 | |
| SSLLASRYDSPINSA | 631 | O14639 | |
| RDSLYASGANLRDSP | 1381 | O94910 | |
| PLSLYGENSNSLSSA | 131 | P18850 | |
| YLLGSARGTSSQPNE | 11 | P26436 | |
| TSSPSGNAYSSLANR | 621 | Q9HBZ2 | |
| ISSYNLQARSPFSLG | 701 | O94779 | |
| KAALNTSAGNSNPYL | 181 | Q5RL73 | |
| SSSGDPAEYNLRSRT | 571 | P02545 | |
| NRLPDSALAGLAYSN | 281 | Q9HCP6 | |
| RAASPQDLAGGYTSS | 276 | P51948 | |
| LRSNYTPRSNGSTDL | 206 | O15151 | |
| AEYGAASPSSAIRTN | 221 | Q9GZZ0 | |
| SPYSTDTLSALRGNS | 951 | Q86Z02 | |
| SYGSSSPALSNRQRF | 266 | Q9UBS5 | |
| SLSPETYGNFDSQSR | 161 | Q96ED9 | |
| SAYNAPSFRAGAQLL | 1941 | Q9Y3R5 | |
| FRSGNYPSSLSNETD | 301 | Q9NS86 | |
| QDASRSPQSLSDTGY | 671 | Q9UPA5 | |
| HGSSLNRTPSDYDLL | 791 | Q13191 | |
| NPCSATYSNLGQSRA | 1101 | Q9H792 | |
| LGYNSNARSNSLRLS | 1931 | O94915 | |
| ASYQAALSLGQDPSN | 76 | Q86SU0 | |
| SGLRNSATGYRQSPD | 86 | Q9UIQ6 | |
| AAGYRPLSASSQSSL | 441 | Q8NCW0 | |
| LENPRLGSQSTNSSY | 176 | P57087 | |
| NRSLSSQSYSPARAA | 801 | Q8TE49 | |
| LSYSLLGSPNQSLFA | 606 | Q9UN70 | |
| ANPAAAAAANLLASY | 316 | Q9UNW9 | |
| SYLLAALGGNSSPSA | 6 | P05387 | |
| YDRHLLPNSGAAATS | 271 | Q9BQ04 | |
| ADYSNQLDPASGTRN | 1296 | Q9C091 | |
| QDGSNLTASQRAYAP | 1181 | P09884 | |
| AENYTRPSSRNSASA | 301 | Q9Y608 | |
| ASARSPRSYLVAGAN | 396 | P06401 | |
| STYFDLPQSSRGNNE | 26 | O15350 | |
| RTSPESLYSDNSNGS | 26 | P20393 | |
| TSGNNLVSPDTDYRA | 481 | Q9H7U1 | |
| ALAASPRQAAYADSG | 6 | Q9BWX5 | |
| IAGNPAYRSFSNSLS | 491 | P24394 | |
| SLVAYINGSRASPAN | 171 | Q8NEA6 | |
| ATPSALQANLNYGSL | 66 | Q5VZ89 | |
| SRAQSLSYALTSPDA | 281 | Q9UPI3 | |
| NSAPSLGLGARTYSQ | 26 | Q96LL9 | |
| DDPSSGNNARLLYSL | 176 | Q9H159 | |
| GYPDSLALANNSTLT | 686 | Q16531 | |
| SSRSYLALPGNSGED | 376 | Q96NU0 | |
| DFSTLYGSSPLERQN | 656 | Q15648 | |
| YGSSPLERQNSSSGS | 661 | Q15648 | |
| TSSTQSLARLGSPDY | 1851 | Q14980 | |
| SANPAAAAANLLATY | 351 | P51513 | |
| SSSAPPRCNNYSANA | 251 | Q9NXJ0 | |
| SSSAAATQRLADYSP | 306 | Q6ZN04 | |
| GPSSQAYDNLSLSDH | 2141 | Q93008 | |
| YSFDRNLGQSLSEPA | 676 | Q58EX7 | |
| NFSPANLSSTGSRYL | 81 | Q96CS2 | |
| SQGLPASRYNTAADA | 1806 | O75376 | |
| NGYELSPTAAANFTR | 71 | P49721 | |
| NDYDNSPTALSRISS | 646 | P81133 | |
| ARSSNYSLPGLTASQ | 241 | Q15475 | |
| LSQNRSSESYRPFSG | 1386 | Q8N3P4 | |
| APASSYNLDVRGARS | 21 | P20701 | |
| QSRLYSNRELGSSPS | 191 | Q5SWA1 | |
| RNVSDYTPLSLAASG | 1151 | Q8IWZ3 | |
| GLYSNPDLSAAASLA | 1026 | Q15021 | |
| TGSRYQPLASTASDN | 1321 | Q15021 | |
| YLGNSLLDSPSQSNS | 251 | Q8IXR9 | |
| SSPTRNLNGAYLTEG | 551 | Q9Y5T5 | |
| SLRSQGYNSSQDLPS | 381 | Q9NTN9 | |
| RSLDANSSGRLPDAY | 746 | Q8N7X1 | |
| SLDANSGGRSPNAYS | 786 | Q8N7X1 | |
| SEGLNNLSSPGSYQR | 26 | Q7Z2H8 | |
| SNSLGRSPSASAYLT | 306 | Q9UPX0 | |
| SSSLNSGNYLNPACR | 546 | Q9UQR0 | |
| RYGSAAALPSNSFTS | 71 | P38935 | |
| SSSDALQGRYAAPEL | 336 | Q86VE9 | |
| GSQALLLRTPYSSDN | 211 | P19544 | |
| NLGSSDPSLRSAAYN | 1861 | P21359 | |
| RSLSNPDYSGTRSNA | 76 | Q6UXY8 | |
| GSSSAPNLQDYARTH | 1071 | O43314 | |
| NRNSRNSSSGVSPLY | 391 | Q9BZH6 | |
| HPSSSNADLLNYRSL | 526 | Q2TAA8 | |
| TPSSYGANLAASLLE | 31 | O75604 | |
| SSSNLQAPGGSSERY | 356 | Q6N021 | |
| RSTLYIAASQPGDSA | 91 | A0A0B4J279 | |
| AFPLAASYDTNGLSQ | 1056 | Q63HR2 | |
| LFGRPSQGLYSSSAS | 2066 | O95071 | |
| HATAGPLYSDNSNIS | 1441 | Q9P2D8 | |
| LGASLANSPYATLAS | 516 | O75132 | |
| NSSHGSPDSYSLLLN | 1231 | Q9ULV0 |